Efficacy News and Research

RSS
GLP-1 receptor agonist boosts glycemic control in Asian patients

GLP-1 receptor agonist boosts glycemic control in Asian patients

Femoropopliteal total occlusion therapy advances

Femoropopliteal total occlusion therapy advances

Patent claims for technology to assess Parkinson’s disease issued to Great Lakes Neurotechnologies

Patent claims for technology to assess Parkinson’s disease issued to Great Lakes Neurotechnologies

AB Science announces data from development program of masitinib in GIST

AB Science announces data from development program of masitinib in GIST

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

MBC receives $50,000 FABC grant to further research into blood donor safety

MBC receives $50,000 FABC grant to further research into blood donor safety

FDA issues complete response letter to Merck’s ridaforolimus NDA

FDA issues complete response letter to Merck’s ridaforolimus NDA

bioTheranostics’ CancerTYPE ID molecular test improves overall survival for patients with CUP

bioTheranostics’ CancerTYPE ID molecular test improves overall survival for patients with CUP

Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma

Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma

SANUWAVE’s ESWT stimulates proliferation of cambium cells for bone generation

SANUWAVE’s ESWT stimulates proliferation of cambium cells for bone generation

Altapure, ITT Exelis to launch new model of disinfection system

Altapure, ITT Exelis to launch new model of disinfection system

Abbott commences elagolix Phase 3 trial in endometriosis

Abbott commences elagolix Phase 3 trial in endometriosis

BioMed Protect’s Sanotracin RTU rapidly and effectively kills C. difficile within 3 minutes

BioMed Protect’s Sanotracin RTU rapidly and effectively kills C. difficile within 3 minutes

Lilly announces final results from ALIMTA Phase III study on NSCLC

Lilly announces final results from ALIMTA Phase III study on NSCLC

Three-drug regimen provides rapid, durable responses for multiple myeloma

Three-drug regimen provides rapid, durable responses for multiple myeloma

BioInvent, ThromboGenics announce results from TB-402 Phase IIb trial on VTE

BioInvent, ThromboGenics announce results from TB-402 Phase IIb trial on VTE

Updated results from three trials of Bruton's ibrutinib for treatment of CLL/SLL

Updated results from three trials of Bruton's ibrutinib for treatment of CLL/SLL

Parkinson’s vaccine: worldwide first clinical trial begins

Parkinson’s vaccine: worldwide first clinical trial begins

Risk of recurrent shingles episode is relatively low: Study

Risk of recurrent shingles episode is relatively low: Study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.